Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis

Hereditary transthyretin‐mediated (hATTR) amyloidosis is a rare, inherited, progressively debilitating, and often fatal disease caused by deposition of mutated transthyretin (TTR) protein. Patisiran is an RNA interference therapeutic comprising a novel small interfering ribonucleic acid (ALN‐18328)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaoping, Goel, Varun, Robbie, Gabriel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187331/
https://www.ncbi.nlm.nih.gov/pubmed/31777097
http://dx.doi.org/10.1002/jcph.1553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187331/
https://www.ncbi.nlm.nih.gov/pubmed/31777097
http://dx.doi.org/10.1002/jcph.1553

Ejemplares similares